Do NSAIDs contribute to acute fatty liver of pregnancy?

Medical Hypotheses

Volumn 54, Issue 5, 2000, Pages 846-849

  Baldwin, G S ^a  

^a A and RMC   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; FATTY ACID; LONG CHAIN FATTY ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN;

FATTY ACID OXIDATION; FATTY LIVER; GENE MUTATION; PREGNANCY; PRIORITY JOURNAL; REVIEW; REYE SYNDROME; STEATOSIS;

EID: 0034073260     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1054/mehy.1999.0965     Document Type: Article

References (38)

1. Wanders R. J. A., Duran M., Ilst L. Sudden infant death and long-chain 3-hydroxyacyl-CoA dehydrogenase. Lancet. ii:1989;52.
2. Jackson S., Kler R. S., Bartlett K. Combined enzyme defect of mitochondrial fatty acid oxidation. J Clin Invest. 90:1992;1219-1225.
3. Wanders R. J. A., Ijlst L., Poggi F. Human trifunctional protein deficiency: A new disorder of mitochondrial fatty acid β-oxidation. Biochem Biophys Res Commun. 188:1992;1139-1145.
4. Tyni T., Palotie A., Viinikka L. Long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency with the G1528C mutation: Clinical presentation of thirteen patients. J Pediatr. 130:1997;67-76.
5. Uchida Y., Lzai K., Orii T., Hashimoto T. Novel fatty acid β-oxidation enzymes in rat liver mitochondria. II. Purification and properties of enoyl-coenzyme A (CoA) hydratase/3-hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase trifunctional protein. J Biol Chem. 267:1992;1034-1041.
6. Kamijo T., Wanders R. J. A., Saudubray J.-M. Mitochondrial trifunctional protein deficiency. Catalytic heterogeneity of the mutant enzyme in two patients. J Clin Invest. 93:1994;1740-1747.
7. Ijlst L., Wanders R. J. A., Ushikubo S., Kamijo T., Hashimoto T. Molecular basis of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: identification of the major disease-causing mutation in the α-subunit of the mitochondrial trifunctional protein. Biochim Biophys Acta. 1215:1994;347-350.
8. Ijlst L., Ruiter J. P. N., Hoovers J. M. N., Jakobs M. E., Wanders R. J. A. Common missense mutation G1528C in long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. Characterization and expression of the mutant protein, mutation analysis on genomic DNA and chromosomal localization of the mitochondrial trifunctional protein α-subunit gene. J Clin Invest. 98:1996;1028-1033.
9. Ushikubo S., Aoyama T., Kamijo T. Molecular characterization of mitochondrial protein deficiency: Formation of the enzyme complex is important for stabilization of both α- and β-subunits. Am J Hum Genet. 58:1996;979-988.
10. Brackett J. C., Sims H. F., Rinaldo P. Two α subunit donor splice site mutations cause human trifunctional protein deficiency. J Clin Invest. 95:1995;2076-2082.
11. Baldwin G. S., Murphy V. J., Yang Z., Hashimoto T. Binding of non-steroidal anti-inflammatory drugs to the α-subunit of the trifunctional protein of long chain fatty acid oxidation. J Pharmacol Exp Ther. 286:1998;1110-1114.
12. Geneve J., Hayat-Bonan B., Labbe G. Inhibition of mitochondrial β-oxidation of fatty acids by pirprofen. Role in microvesicular steatosis due to this nonsteroidal anti-inflammatory drug. J Pharmacol Exp Ther. 242:1987;1133-1137.
13. Freneaux E., Fromenty B., Berson A. Stereoselective and nonstereoselective effects of ibuprofen enantiomers on mitochondrial β-oxidation of fatty acids. J Pharmacol Exp Ther. 255:1990;529-535.
14. Zhao B., Geisslinger G., Hall I., Day R. O., Williams K. M. The effect of enantiomers of ibuprofen and flurbiprofen on the β-oxidation of palmitate in the rat. Chirality. 4:1992;137-141.
15. Yang Z., Hollande F., Baldwin G. S. Blockade of long chain fatty acid oxidation by non-steroidal anti-inflammatory drugs may contribute to inhibition of proliferation of human colorectal carcinoma cell lines. Cancer Lett. 124:1998;187-191.
16. Deschamps D., Fisch C., Fromenty B. Inhibition by salicylic acid of the activation and thus oxidation of long chain fatty acids. Possible role in the development of Reye's syndrome. J Pharmacol Exp Ther. 259:1991;894-904.
17. Rolfes D. B., Ishak K. G. Acute fatty liver of pregnancy: A clinicopathologic study of 35 cases. Hepatology. 5:1985;1149-1158.
18. Wilcken B., Leung K.-C., Hammond J., Kamath R., Leonard J. V. Pregnancy and fetal long-chain 3-hydroxyacyl coenzyme A dehydrogenase deficiency. Lancet. 341:1993;407-408.
19. Treem W. R., Rinaldo P., Hale D. E. Acute fatty liver of pregnancy and long-chain 3-hydroxyacylcoenzyme A dehydrogenase deficiency. Hepatology. 19:1994;339-345.
20. Treem W. R., Shoup M. E., Hale D. E. Acute fatty liver of pregnancy, hemolysis, elevated liver enzymes, and low platelet syndrome, and long chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency. Am J Gastroenterol. 91:1996;2293-2300.
21. Sims H. F., Brackett J. C., Powell C. K. The molecular basis of pediatric long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency associated with maternal acute fatty liver of pregnancy. Proc Natl Acad Sci USA. 92:1995;841-845.
22. Isaacs J. D., Sims H. F., Powell C. K. Maternal acute fatty liver of pregnancy, associated with fetal trifunctional protein deficiency. Pediatric Res. 40:1996;393-398.
23. Tyni T., Ekholm E., Pihko H. Pregnancy complications are frequent in long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency. Am J Obstet Gynecol. 178:1998;603-608.
24. Reye R. D. K., Morgan G., Baral J. Encephalopathy and fatty degeneration of the viscera. A disease entity in childhood. Lancet. ii:1963;749-752.
25. Mowat A. P. Reye's syndrome. BMJ. 286:1983;1999-2001.
26. Heubi J. E., Partin J. C., Partin J. S., Schubert W. K. Reye's syndrome: current concepts. Hepatology. 7:1987;155-164.
27. Glasgow J. F. T., Moore R. Reye's syndrome 30 years on. Possible marker of inherited metabolic disorders. BMJ. 307:1993;950-951.
28. Hardie R. M., Newton L. H., Bruce J. C. The changing pattern of Reye's syndrome 1982-1990. Arch Dis Child. 74:1996;400-405.
29. Starko K. M., Ray C. G., Dominguez L. B., Stromberg W. L., Woodall D. F. Reye's syndrome and salicylate use. Pediatrics. 66:1980;859-864.
30. Waldman R. J., Hall W. N., McGee H., Van Amburg G. Aspirin as a risk factor in Reye's syndrome. JAMA. 247:1982;3089-3094.
31. Halpin T. J., Holtzhauer F. J., Campbell R. J. Reye's syndrome and medication use. JAMA. 248:1982;687-691.
32. Green A., Hall S. M. Investigation of metabolic disorders resembling Reye's syndrome. Arch Dis Childhood. 67:1992;1313-1317.
33. Tonsgard J. H., Getz G. S. Effect of Reye's syndrome serum on isolated Chinchilla liver mitochondria. J Clin Invest. 76:1985;816-825.
34. Corkey B. E., Hale D. E., Glennon M. C. Relationship between unusual hepatic acyl coenzyme A profiles and the pathogenesis of Reye syndrome. J Clin Invest. 82:1988;782-788.
35. Yoshida Y., Fujii M., Brown F. R., Singh I. Effect of salicylic acid on mitochondrial-peroxisomal fatty acid catabolism. Paediatr Res. 23:1988;338-341.
36. Hermesh O., Kalderon B., Bar-Tana J. Mitochondrial uncoupling by a long chain fatty acyl analogue. J Biol Chem. 273:1998;3937-3942.
37. Smith W. L., Garavito R. M., DeWitt D. L. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem. 271:1996;33157-33160.
38. Zhang Q.-X., Baldwin G. S. Structure of the human cDNA and gene encoding the 78 kDa gastrin-binding protein and of a related pseudogene. Biochim Biophys Acta. 1219:1993;567-575.